Medical Developments International Limited Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada

Ontario Industry Updates
Written By Guest User

Sept 11, 2016 Medical Developments International Limited ("MDI") (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in Canada. 

Penthrox® is a fast-acting, inhaled, non-narcotic analgesic drug/device combination for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  

The CEO of MDI, Mr. John Sharman said: "This is an exciting deal for MDI and is a critical step towards providing the Canadian healthcare system with another valuable therapeutic option for the treatment of pain. Purdue has market leading expertise in pain management products and will invest in providing the educational resources to healthcare practitioners on the appropriate use, benefits, and safety profile of Penthrox."

For the full press release, click here

Guest User
Previous

CAAP Company: Tecla is helping those who live with Multiple Sclerosis
Next

Self Care Catalysts: App to Support Self-Management for Primary Biliary Cholangitis (PBC)